Fatal haemorrhagic pulmonary oedema and associated angioedema after the ingestion of rofecoxib.
Angioedema is a recognised side effect of rofecoxib, a cyclo-oxygenase-2 (COX-2) inhibitor. But death resulting from a haemorrhagic pulmonary oedema after its ingestion has not been recorded. The case of a 60 year old man who died from haemorrhagic pulmonary oedema in the presence of angioedema after the ingestion of two doses of 12.5 mg of rofecoxib is reported.
Kumar
N P
NP
General and Geriatric Medicine, King's Mill Hospital, Sutton in Ashfield, Nottinghamshire, UK.
Wild
G
G
Ramasamy
K A
KA
Snape
J
J
D000799:Angioedema / Q000139:chemically induced*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D017809:Fatal Outcome; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D008171:Lung Diseases / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D011654:Pulmonary Edema / Q000139:chemically induced*; D013450:Sulfones
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib